Context Therapeutics Inc (CNTX)

07:37 AM

Visual analytics tools that track Context Therapeutics Inc. performanceEarnings Growth Report & Smart Investment Allocation Insights - Newser

07:37 AM

06:02 AM

What makes Context Therapeutics Inc. stock price move sharply2025 Retail Activity & Weekly High Momentum Picks - Newser

06:02 AM

03:51 AM

Analyzing net buyer seller activity in Context Therapeutics Inc.2025 Trade Ideas & Real-Time Stock Movement Alerts - Newser

03:51 AM

12:51 PM

Full technical analysis of Context Therapeutics Inc. stockJuly 2025 Movers & High Accuracy Swing Entry Alerts - Newser

12:51 PM

Aug 13, 2025

Applying sector rotation models to Context Therapeutics Inc.Entry Point & Free Verified High Yield Trade Plans - Newser

Aug 13, 2025

Aug 13, 2025

What technical models suggest about Context Therapeutics Inc.’s comebackRate Cut & Weekly Chart Analysis and Trade Guides - Newser

Aug 13, 2025

Aug 13, 2025

How Context Therapeutics Inc. stock performs during market volatilityQuarterly Profit Summary & Weekly Top Performers Watchlists - Newser

Aug 13, 2025

Aug 13, 2025

Best data tools to analyze Context Therapeutics Inc. stockWeekly Volume Report & Free Reliable Trade Execution Plans - Newser

Aug 13, 2025

Aug 13, 2025

How to read the order book for Context Therapeutics Inc.Earnings Risk Summary & Expert Curated Trade Setup Alerts - Newser

Aug 13, 2025

Aug 13, 2025

Chart based exit strategy for Context Therapeutics Inc.2025 Institutional Moves & Fast Momentum Stock Entry Tips - Newser

Aug 13, 2025

Aug 13, 2025

Context Therapeutics Highlights Pipeline Progress, Reports $8.8M Loss in Q2 - MSN

Aug 13, 2025

Aug 13, 2025

Quantitative breakdown of Context Therapeutics Inc. recent moveRate Cut & Real-Time Volume Analysis - Newser

Aug 13, 2025

Aug 13, 2025

Context Therapeutics Inc. shares fall 1.47% premarket after Anavex Life Sciences reports fiscal 2025 third quarter results. - AInvest

Aug 13, 2025

Aug 12, 2025

Tools to monitor Context Therapeutics Inc. recovery probabilityAI Intraday Market Movement Prediction Tool - Newser

Aug 12, 2025

Aug 11, 2025

Context Therapeutics Inc. Stock Support and Resistance Levels You Should KnowAI Generated Buy/Sell Signal Forecast - Newser

Aug 11, 2025

Aug 11, 2025

William Blair Has Pessimistic Outlook of CNTX Q3 Earnings - Defense World

Aug 11, 2025

Aug 10, 2025

How sentiment analysis helps forecast Context Therapeutics Inc.Buy Entry Confirmation Based on Technical Analysis - Newser

Aug 10, 2025

Aug 10, 2025

HC Wainwright Cuts Context Therapeutics (NASDAQ:CNTX) Price Target to $4.00 - Defense World

Aug 10, 2025

Aug 10, 2025

Context Therapeutics’ (CNTX) “Buy” Rating Reiterated at D. Boral Capital - Defense World

Aug 10, 2025

Aug 10, 2025

Published on: 2025-08-10 04:36:20 - Newser

Aug 10, 2025

Aug 10, 2025

Why Context Therapeutics Inc. stock attracts strong analyst attentionFree Real Time Alerts Based on AI Prediction - Newser

Aug 10, 2025

Aug 08, 2025

Context Therapeutics Inc. shares fall 2.58% intraday as Genmab's epcoritamab development program progresses. - AInvest

Aug 08, 2025

Aug 07, 2025

Detecting support and resistance levels for Context Therapeutics Inc.Capital Growth Summary Over Five Years - Newser

Aug 07, 2025

Aug 07, 2025

D. Boral Capital Raises PT to $9 on Context Therapeutics - AInvest

Aug 07, 2025

Aug 07, 2025

Context Therapeutics: HC Wainwright Downgrades to Buy with $4 PT. - AInvest

Aug 07, 2025

Aug 06, 2025

Context Therapeutics Q2 net loss widens, cash funds ops into 2027 - MarketScreener

Aug 06, 2025

Aug 06, 2025

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results - GlobeNewswire

Aug 06, 2025

Aug 06, 2025

Context Therapeutics Q2 Earnings: Strong $83.5M Cash Position Funds Two Key Cancer Drug Trials - Stock Titan

Aug 06, 2025